Vanda Pharmaceuticals Inc. (VNDA) fair value analysis

Nasdaq · Updated 2026-09-07

Vanda Pharmaceuticals Inc. is a biopharmaceutical company that develops and commercializes prescription medications for central nervous system disorders and other therapeutic areas. The company operates primarily in the United States and maintains operations to support its product development and marketing activities across multiple markets.

Forward Fair Value verdict

Undervalued

Based on TickrTrends' weekly Forward Fair Value model, VNDA is trading at a 10–25% discount to estimated fair value.

VNDA currently ranks #36 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Undervalued for 3 consecutive weekly runs.

Last price: $5.23
Sector: Healthcare
12-month range: $4.47–$8.25

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: D
Leverage: Low
RSI zone: Neutral
50/200-day trend: Mixed
52-week position: The bottom quarter of its range

What our data shows for VNDA

Our model validated 7 trailing price-to-earnings windows for VNDA, built from quarterly earnings records.
Shares are trading in the lower third of their 12-month price range of $4.47–$8.25.
The 14-day relative strength index sits at a neutral 56.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for VNDA
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent VNDA news

TickrTrends' derived news-sentiment signal for VNDA is currently mixed, computed from recent coverage.

Morning Market Movers: SDOT, PMI, RFAI, RGNX See Big Swings (rttnews.com, 2026-08-24)
TickrTrends take: VNDA was not mentioned in this morning's market movers headline, suggesting the stock may be trading with less volatility or market attention compared to peers like SDOT, PMI, RFAI, and RGNX. Given TickrTrends' current undervalued assessment in the Healthcare sector, investors focused on valuation metrics should monitor whether VNDA's relative stability reflects genuine fundamental strength or represents an opportunity being overlooked amid broader market sector movement. The absence from notable swing activity could present a meaningful divergence between market perception and the stock's assessed intrinsic value.
Vanda Pharmaceuticals Inc. (VNDA) Q2 2026 Earnings Call Transcript (seekingalpha.com, 2026-08-06)
TickrTrends take: Vanda Pharmaceuticals operates in the Healthcare sector where earnings visibility and pipeline progress typically drive valuation multiples. TickrTrends currently rates VNDA as undervalued, suggesting the market may not be fully reflecting the company's earnings potential or near-term catalysts that could emerge from detailed quarterly discussion. Investors focused on valuation metrics should monitor management commentary on revenue trends, product performance, and any updates to guidance that might validate or challenge the current undervalued assessment.
Vanda Pharmaceuticals Inc. Q2 2026 Earnings Call Summary (finance.yahoo.com, 2026-08-06)
TickrTrends take: Vanda Pharmaceuticals operates in the Healthcare sector where earnings performance directly influences the fundamental metrics that underpin valuation assessments. TickrTrends currently indicates the stock is Undervalued, making Q2 2026 results particularly relevant as they may reveal whether the company's financial performance justifies or challenges that current valuation positioning. Investors focused on valuation should monitor how the company's revenue trends, profitability metrics, and forward guidance compare to the expectations embedded in the stock's current price.

What people are saying

Follow the VNDA conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — No material change this week: the verdict, bands and grades all held steady.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is VNDA stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), VNDA is trading at a 10–25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.

What is VNDA's TickrTrends verdict?

VNDA's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.

How does VNDA compare to other Healthcare stocks?

VNDA ranks #36 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is VNDA overbought or oversold?

VNDA's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

VNDA vs ABT · VNDA vs CI · VNDA vs DVA · VNDA vs GEHC · VNDA vs INCY